Citadel Advisors
SURF

Citadel Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Citadel Advisors’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-800
Closed -$559 – 15590
2023
Q1 		$559 Sell
800
-3,200
-80% -$2.59K ﹤0.01% 14466
2022
Q4 		$3.28K Buy
+4,000
New +$3.94K ﹤0.01% 14232
2022
Q3 		– Sell
-18,400
Closed -$30K – 13978
2022
Q2 		$30K Sell
18,400
-17,400
-49% -$36.1K ﹤0.01% 12233
2022
Q1 		$105K Sell
35,800
-12,600
-26% -$44.2K ﹤0.01% 12244
2021
Q4 		$231K Sell
48,400
-2,100
-4% -$13.6K ﹤0.01% 11554
2021
Q3 		$382K Sell
50,500
-42,100
-45% -$269K ﹤0.01% 10527
2021
Q2 		$691K Sell
92,600
-5,900
-6% -$45.5K ﹤0.01% 9272
2021
Q1 		$768K Buy
98,500
+20,600
+26% +$206K ﹤0.01% 8738
2020
Q4 		$720K Buy
+77,900
New +$677K ﹤0.01% 7449

Other funds holding SURF

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's SURF Position: Q2 2023 in Review

Citadel Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2023, closing a stake of 118,652 shares — an estimated $82.9K sold.

Citadel Advisors first reported a position in SURF in Q2 2018 and held it in 18 quarters. The position peaked at $14.1M in Q2 2018. 61 funds tracked by Wall St. Rank hold SURF as of Q2 2023.

  • Citadel Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 118,652 Surface Oncology, Inc. Common Stock shares in Q2 2023, an estimated $82.9K.
  • Citadel Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
  • Citadel Advisors's Surface Oncology, Inc. Common Stock position peaked at $14.1M in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.